Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR3 | Q9UBY5 | 2/20 | 0.50 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.50 |
| ▸ | PPARA | Q07869 | 11/20 | 0.48 |
| ▸ | PPARG | P37231 | 8/20 | 0.48 |
| ▸ | PPARD | Q03181 | 5/20 | 0.48 |
| ▸ | PDE4A | P27815 | 2/20 | 0.46 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.46 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.46 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.46 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.46 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.44 |
| ▸ | CYSLTR2 | Q9NS75 | 3/20 | 0.44 |
| ▸ | CYSLTR1 | Q9Y271 | 3/20 | 0.44 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7070000 | 0.92 | PPARA (0.58) | LPAR3LPAR1PPARAPPARGPPARD | |
| SCHEMBL7069921 | 0.86 | ALOX15 (0.41) | LPAR3LPAR1PDE4APDE4BPDE3B | |
| SCHEMBL7072259 | 0.80 | ADAM17 (0.56) | PPARAPPARGPPARDPDE10AADAM17 | |
| SCHEMBL16429583 | 0.80 | MAOB (0.55) | LPAR3PPARAPPARGPPARD | |
| SCHEMBL22061729 | 0.80 | MAOB (0.55) | LPAR3PPARAPPARGPPARD | |
| SCHEMBL4758109 | 0.78 | PPARA (0.75) | PPARAPPARGPPARD | |
| SCHEMBL5338861 | 0.78 | PPARA (0.75) | PPARAPPARGPPARD | |
| SCHEMBL15811673 | 0.78 | PPARA (0.75) | PPARAPPARGPPARD | |
| SCHEMBL7070005 | 0.78 | ALOX15 (0.43) | LPAR3LPAR1PPARAPPARGPPARD | |
| SCHEMBL6555798 | 0.77 | KDM4E (0.59) | PPARAPPARGPPARDPDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030212100-A1 | Quinoline derivatives and medicinal use thereof | MITSUI CHEMICALS, INC. (JP) | 2003-11-13 | — | — | US | disclosed |
| EP-1266888-A1 | QUINOLINE DERIVATIVES AND MEDICINAL USE THEREOF | Mitsui Chemicals, Inc. (JP) | 2002-12-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030212100-A1 | Quinoline derivatives and medicinal use thereof | PPARG, PPARD, PPARA | LPAR3 3405/4885LPAR1 2972/4885PPARA 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.